Loading

What to expect in your first 3 months with Cavadex

When you begin your journey with Cavadex, your body starts a very specific, phase-by-phase process of vascular rejuvenation. Based on our data and direct customer feedback, here is exactly what you can expect to experience over the next 90 days:

Month 1: Cellular Relief & Rapid Blood Pressure Improvement

The first 4 weeks are all about reducing local inflammation and opening up circulation. Many users report a rapid improvement and stabilization in their blood pressure numbers as their arteries begin to lose their rigid stiffness. Within weeks, you can also expect a noticeable drop in the frequency of chest pain (angina) and shortness of breath as your body's natural blood vessel dilation reactivates.

Month 2: Surge in Energy & Physical Vitality

By the second month, systemic vascular health takes a major leap forward. Over 85% of tracked individuals report a significant surge in physical energy. Whether it is returning to standard exercise, walking longer distances without leg cramps, or experiencing sharper mental clarity, your daily quality of life shifts noticeably.

Month 3: Measurable Stabilization

By the 90-day mark, these changes solidify into lasting structural improvements. This is the window where objective medical imaging (like ultrasounds or CT scans) begins to show actual deviations from your old baseline—reflecting a physical reduction in plaque volume and a wider, cleaner arterial pathway. Standard blood panels also typically show a profound optimization across total cholesterol, LDL, and triglycerides.

Cavadex doesn't just manage symptoms; it actively cleans the plumbing and restores your blood vessels' natural flexibility.

WORLD BREAKTHROUGH

World-First Treatment Reverses Coronary Artery Calcium Scores

Cardiology Will Never Be the Same

I am thrilled to announce the publication of a peer-reviewed paper that marks a historic turning point in the fight against atherosclerotic cardiovascular disease (ASCVD), the world's leading cause of death.

This study delivers irrefutable real-world evidence of something previously deemed biologically impossible: true regression of coronary artery calcium (CAC) scores.

The Unbreakable Rule of Cardiology – Until Now

For decades, the scientific consensus has been clear and unyielding:

  • Once coronary artery calcification is detectable on a CT scan, it never goes down.
  • CAC scores progress relentlessly year after year, typically at 14–25% annually (often 20–30% in higher-risk individuals).
  • Spontaneous, clinically meaningful regression is essentially non-existent.
  • Even the most aggressive standard therapies (high-intensity statins, PCSK9 inhibitors) do not reverse CAC they can only slow progression.
    •

    This dogma has shaped cardiology for generations: calcification is irreversible and a permanent marker of accumulated disease.

    Cavadex Changes Everything

    In this multi-center observational case series, patients with advanced, symptomatic ASCVD using the high-viscosity rectal formulation of Cavadex achieved rapid reversal of calcified plaque burden:

  • Absolute CAC reductions of up to 320 points in less than 12 months.
  • Dramatic trajectory reversals — e.g., from consistent +27–28% annual progression pre-treatment to -10.5% regression post-initiation (a -38% swing).
  • Net regression far exceeding expected progression (e.g., -865 units vs. projected +545-unit increase in one case).
  • Rapid structural changes in select patients, including a 70-point drop in just 9 weeks.
    •

    These are not subtle shifts — they represent biological reversal of established calcified atheroma, a phenomenon never before demonstrated in humans with any therapy.

    Why This Is World-Changing

    CAC is the single strongest non-invasive predictor of heart attack, stroke, and cardiovascular death. Reversing it means we are no longer merely slowing the inevitable — we are actively removing decades of plaque burden.

  • For the millions in "end-stage" decline — refractory angina, multivessel disease unsuitable for intervention, statin intolerance — this could be the first true disease-modifying therapy.
  • Substantial improvements observed within months, not years.
  • Potential to prevent countless major events, extend healthy lifespans, and slash the global burden of the #1 killer (around 19 million deaths annually).
    •

    Cardiology will never be the same. We are witnessing the dawn of a new era: from "manage progression" to "reverse the disease."

    The full peer reviewed paper, including detailed longitudinal CAC trajectory tables and historical controls, is now published and publicly accessible

    Peer reviewed paper

    This is not hype. This is science that will save millions of lives.

    If you are a clinician, researcher, journalist or advocate interested in this breakthrough, I welcome the opportunity to discuss the data.

    Best Regards,
    Kyle